Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 in Patients With Advanced Solid Tumors

NCT04837677 is registered in ClinicalTrials.gov with Prelude Therapeutics as lead sponsor.

NCT NCT04837677
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04837677 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 in Patients With Advanced Solid Tumors
Lead sponsor
Prelude Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
August 11, 2021
Completion date
February 6, 2023
Enrollment
26 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cervical cancer, esophageal cancer, head and neck cancer, lung cancer, melanoma, sarcoma